Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu, +13

Journal of Clinical Investigation

EngineeringEgfr-amplified Lung CancerPathologyCancer BiologyTumor Biology +18

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

Lecia V. Sequist, Rebecca S. Heist, Alice T. Shaw, +30

Annals of Oncology

Non-small-cell Lung CancersCancer DetectionMedicinePathologyCancer Genomics +9

EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

April F. Eichler, Kristopher T. Kahle, D. L. Wang, +5

Neuro-Oncology

Surgical OncologyCell Lung CancerMedicineBrain MetastasisPathology +10

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

Mark G. Kris, B. E. Johnson, D J Kwiatkowski, +17

Journal of Clinical Oncology

Surgical OncologyCancer PathologyCancer ManagementLung AdenocarcinomaImmunology +16

Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda, +17

European Journal of Cancer

OncologyAlk-rearranged Lung CancerMolecular MechanismsMedicineBronchial Neoplasm +7

A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

Karen L. Reckamp, Giuseppe Giaccone, D. Ross Camidge, +13

Cancer

OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, +7

European Journal of Cancer

Signaling PathwayMedicineReceptor Tyrosine KinaseImmunologyImmunotherapy +4

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

Heather A. Wakelee, Scott Gettinger, J. A. Engelman, +7

Journal of Clinical Oncology

ImmunologyPathologyPharmacotherapyMetronomic ChemotherapyTumor Biology +21

A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Richard B. Cohen, Pasi A. Jänne, J. A. Engelman, +4

Journal of Clinical Oncology

Tumor BiologyMedicineMetronomic TherapyPharmacologyCancer Cell Biology +13

EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer.

April F. Eichler, Kristopher T. Kahle, D. L. Wang, +3

Journal of Clinical Oncology

Neuro-oncologyNsclc Harbor MutationsMedicineBrain MetastasisPathology +13